address1,address2,city,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,lastDividendValue,lastDividendDate,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,shortName,longName,corporateActions,marketState,regularMarketChangePercent,regularMarketPrice,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,hasPrePostMarketData,firstTradeDateMilliseconds,regularMarketTime,exchange,messageBoardId,cryptoTradeable,trailingPegRatio
Lunastigen 5,2nd Floor,Huddinge,Sweden,46 8 54 68 31 00,https://www.medivir.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.",10,"[{'maxAge': 1, 'name': 'Mr. Jens  Lindberg', 'age': 53, 'title': 'Chief Executive Officer', 'yearBorn': 1971, 'fiscalYear': 2024, 'totalPay': 3938000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Magnus  Christensen', 'age': 50, 'title': 'Chief Financial Officer', 'yearBorn': 1974, 'fiscalYear': 2024, 'totalPay': 2657000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fredrik  Ã–berg', 'age': 59, 'title': 'Chief Scientific Officer', 'yearBorn': 1965, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Pia  Baumann', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Karin  Tunblad', 'title': 'Senior Principal Scientist & MIV-818 Project Leader', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,4,1.522,1.52,1.48,1.548,1.522,1.52,1.48,1.548,831600000,0.0,-0.24,-1.2390244,52126,52126,203388,114693,114693,1.5,1.524,170944032,1.06,3.99,47.696438,1.68816,2.215655,0.0,0.0,SEK,False,147881776,0.0,89352873,112168000,0.22169,0.22483999,112168000,0.915,1.6655738,1735603200,1767139200,1743379200,-110517000,-0.97,-1.23,41.262,-1.289,-0.46898955,0.11708844,0.221198,831600000,EQUITY,1.524,54.0,5.0,18.8525,8.205,none,4,35100000,0.313,-114711248,8000000,1.162,1.162,3584000,7.797,0.031,-0.34774,-0.70371,-83089000,-78082376,-115991000,0.2,0.0,0.0,-22.66667,SEK,MVIR.ST,en-US,US,Equity,Delayed Quote,True,HIGH,0.0020000935,1.48 - 1.548,Stockholm,203388,0.4640001,0.43773597,1.06 - 3.99,-2.466,-0.61804515,-46.898956,1755757800,1755757800,1755757800,1755773940,1755773940,False,-0.97,-1.23,-0.745,-2.0456376,-0.1641599,-0.09724191,-0.69165504,-0.3121673,15,0,Medivir AB,Medivir AB (publ),[],PREPRE,0.1314122,1.524,Europe/Stockholm,CEST,7200000,se_market,False,False,946886400000,1751902170,STO,finmb_2480879,False,
